SCHEMBL1747012

SCHEMBL1747012

CCCCCCCCCCC(=O)O[Si](CC)(CC)OC(=O)CCCCCCCCCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.55
LMNA P02545 2/20 0.52
PAM P19021 2/20 0.50
MAPT P10636 2/20 0.48
MAPK1 P28482 1/20 0.48
CES2 O00748 3/20 0.48
CES1 P23141 3/20 0.48
TSHR P16473 5/20 0.47
PPARG P37231 6/20 0.46
PPARD Q03181 6/20 0.46
PPARA Q07869 6/20 0.46
HDAC11 Q96DB2 5/20 0.46
GPR84 Q9NQS5 4/20 0.46
ALDH1A1 P00352 2/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
FABP4 P15090 2/20 0.46
PTPN1 P18031 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745930 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL1747417 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL1746020 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL1746182 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL1746036 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL1747165 1.00 DGKA (0.55) DGKALMNAPAMMAPTMAPK1
SCHEMBL5080872 0.86 DGKA (0.53) DGKALMNAPAMMAPTMAPK1
SCHEMBL5074853 0.86 DGKA (0.53) DGKALMNAPAMMAPTMAPK1
SCHEMBL5077124 0.86 DGKA (0.53) DGKALMNAPAMMAPTMAPK1
SCHEMBL6243474 0.83 DGKA (0.55) DGKALMNAPAMMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948196-B1 USE OF TETRAORGANOSILICON COMPOUNDS SALAMA ZOSER B (DE) 2012-12-26 EP claimed
EP-2563337-B1 CARRIER AND TARGETING SYSTEM COMPRISING A SIOSOMAL COMPOSITION FOR INTRACELLULAR DELIVERY AND TARGETING OF ACTIVE SUBSTANCE SALAMA ZOSER B (DE) 2017-07-26 EP disclosed
EP-2563337-B1 CARRIER AND TARGETING SYSTEM COMPRISING A SIOSOMAL COMPOSITION FOR INTRACELLULAR DELIVERY AND TARGETING OF ACTIVE SUBSTANCE SALAMA ZOSER B (DE) 2017-07-26 EP disclosed
EP-2384743-A1 Siosomal formulation for intracellular delivery and targeting of therapeutic agents Salama, Zoser B. (DE) 2011-11-09 EP disclosed
US-20100247578-A1 CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF SALAMA ZOSER B 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100247578-A1 CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF EXOSC5, EXOSC9, SSB DGKA 3104/4885LMNA 1390/4885PAM 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.